A cancer associated fibroblast (CAF) inhibitor for use with an alternating electric field in a method of treating diseases such as cancer

HK40137324APending Publication Date: 2026-09-11NOVOCURE GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026122705
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-29
Filing Date
2026-04-29
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed are methods of treating a subject in need thereof comprising applying an alternating electric field, at a frequency for a period of time, to a target site of the subject in need thereof; and administering a cancer associated fibroblast (CAE) inhibitor to the subject in need thereof. Disclosed are methods of reducing or preventing CAE activation comprising applying alternating electric fields, at a frequency for a period of time, to a population of cells comprising one or more fibroblasts; and contacting a CAE activation inhibitor to the population of cells. Disclosed are methods of reducing CAE signaling comprising applying alternating electric fields, at a frequency for a period of time, to a population of cells comprising one or more fibroblasts; and contacting a cancer associated fibroblast (CAE) signaling inhibitor to the population of cells.
Need to check novelty before this filing date? Find Prior Art

Description

The abstract discloses methods for treating subjects in need, comprising: applying an alternating electric field of a certain frequency for a certain duration to a target site of the subject in need; and administering a cancer-associated fibroblast (CAF) inhibitor to the subject in need. It also discloses methods for reducing or preventing CAF activation, comprising: applying an alternating electric field of a certain frequency for a certain duration to a cell population containing one or more fibroblasts; and contacting the cell population with a CAF activation inhibitor. Finally, it discloses methods for reducing CAF signaling, comprising: applying an alternating electric field of a certain frequency for a certain duration to a cell population containing one or more fibroblasts; and contacting the cell population with a cancer-associated fibroblast (CAF) signaling inhibitor.

Claims

CLAIMSWe claim:

1. A cancer associated fibroblast (CAF) inhibitor for use with an alternating electric field in a method of treating a subject in need thereof.

2. An alternating electric field together with a cancer associated fibroblast inhibitor for use in a method of treating a subject in need thereof.

3. The CAF inhibitor of claims 1 or the alternating electric field together with a CAF inhibitor of claim 2, wherein the target site comprises one or more cancer cells.

4. The CAF inhibitor of claims 1 or the alternating electric field together with a CAF inhibitor of claim 2, wherein the CAF inhibitor is a CAF activation inhibitor or a CAF signaling inhibitor.

5. The CAF inhibitor of claim 4 or the alternating electric field together with a CAF inhibitor of claim 4, wherein the CAF activation inhibitor is a fibroblast activation protein (FAP) inhibitor, a selective PDGFRb inhibitor, a Hsp90 inhibitor, a LRRC15 inhibitor, a selective Hedgehog inhibitor, a selective Hyaluronic acid secretion inhibitor, or an IL-1R inhibitor.

6. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the FAP inhibitor is Talabostat, FAP -2286, or TAM558.

7. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the selective PDFGRb inhibitor is sPDGFRblg, Crenolanib, Orantinib, CP-673451, SU16f, Tyrphostin AG 1296, Tyrphostin AG1433 or Seralutinib.

8. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the Hsp90 inhibitor is XL888, Geldanamycin, Gedunin, Tanespimycin, Luminespib, BIIV 021, CCT 018159, or 17-AAG.

9. The CAF inhibitor of claim 5 or the alternating electric field together with a CAF inhibitor of claim 5, wherein the LRRC15 inhibitor is ABBV-085 antibody.

10. The CAF inhibitor of claim 4 or the alternating electric field together with a CAF inhibitor of claim 4, wherein the CAF signaling inhibitor is a Lysyl oxidase (LOX)inhibitor, a Lysyl oxidase like (LOXL) inhibitor, CXCR4 inhibitor or CXCR12 inhibitor.

11. The CAF inhibitor of claims 1-10 or the alternating electric field together with a CAF inhibitor of claims 2-10, wherein the target site comprises one or more cancer cells.

12. The CAF inhibitor of claims 1-11 or the alternating electric field together with a CAF inhibitor of claims 2-11, wherein the CAF activation inhibitor inhibits or decreases fibroblast activation protein (FAP), alpha smooth muscle actin (aSMA), or platelet derived growth factor receptor beta (PDGFRb) expression, and / or prevents PDGFRb from interacting with or binding to PDGF, and / or prevents Hsp90 from ATPase activity that upregulates fibroblast activation.

13. The CAF inhibitor of claims 1-12 or the alternating electric field together with a CAF inhibitor of claims 2-12, wherein the frequency of the alternating electric field is between 50 kHz and 1 MHz.

14. The CAF inhibitor of claims 1-13 or the alternating electric field together with a CAF inhibitor of claims 2-13, wherein the alternating electric field has a field strength of between 0.5 and 10 V / cm RMS.

15. The CAF inhibitor of claims 1-14 or the alternating electric field together with a CAF inhibitor of claims 2-14, wherein the CAF inhibitor prevents Lox or Loxl from covalently cross-linking collagen and elastin in extracellular matrix (ECM).